GERN - Geron Corporation logo

GERN

Geron Corporation

Geron Corporation develops therapeutics for oncology, focusing on hematologic malignancies. Its pipeline includes RYTELO for myelodysplastic syndromes and several candidates in various clinical trial phases for related blood cancers.

โš•๏ธ Healthcare NASDAQ Listed 1996 $ USD
$1,000 invested 30 years ago โ†’$241today

Score Overview

1 Year
Score
Net Growth18.52%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth11.25%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.8
Net Growth39.80%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth146x
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-136.63%
Net Trend50%
Net Income Consistency
Rev Growth33x
Rev Trend50%
Revenue Consistency
20 Years
Score2.9
Net Growth-122.84%
Net Trend50%
Net Income Consistency
Rev Growth62x
Rev Trend45%
Revenue Consistency
30 Years
Score
Net Growth-4x
Net Trend57%
Net Income Consistency
Rev Growth38x
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-4x
Net Trend57%
Net Income Consistency
Rev Growth38x
Rev Trend40%
Revenue Consistency

See the full market ranking โ†’

Geron Corporation fundamental performance

Between 2020 and 2025, revenue grew from $ 253K to $ 183M and net income went from -$ 75M to -$ 85M. Revenue increased in 3 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 36M to $ 183M and net income went from $ 46K to -$ 85M. Revenue increased in 5 of those 10 years; net income in 5.

Geron Corporation currently holds a 20-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-13
$ 1.53โ€”
1 Year2025-08-13
$ 1.437.34%
5 Years2021-08-13
$ 1.2225.82%
10 Years2016-08-12
$ 2.74-43.98%
20 Years2006-08-11
$ 5.58-72.51%
30 Years1996-08-13
$ 6.38-75.93%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 204M-$ 69M$ 300M
2025$ 183M-$ 85M$ 359M
2024$ 76M-$ 174M$ 406M
2023$ 237K-$ 184M$ 333M
2022$ 596K-$ 141M$ 172M
2021$ 1M-$ 116M$ 183M
2020$ 253K-$ 75M$ 196M
2019$ 460K-$ 63M$ 139M
2018$ 1M-$ 27M$ 163M
2017$ 1M-$ 27M$ 94M
2016$ 6M-$ 29M$ 115M
2015$ 36M$ 46K$ 114M
2014$ 1M-$ 35M$ 151M
2013$ 1M-$ 38M$ 65M
2012$ 2M-$ 68M$ 96M
2011$ 2M-$ 96M$ 121M
2010$ 3M-$ 111M$ 186M
2009$ 1M-$ 70M$ 111M
2008$ 2M-$ 62M$ 162M
2007$ 7M-$ 36M$ 206M
2006$ 3M-$ 31M$ 213M
2005$ 290K-$ 33M$ 190M
2004$ 1M-$ 80M$ 119M
2003$ 1M-$ 29M$ 109M
2002$ 1M-$ 33M$ 46M
2001$ 3M-$ 42M$ 68M
2000$ 6M-$ 45M$ 33M
1999$ 5M-$ 46M$ 7M
1998$ 6M-$ 10M$ 16M
1997$ 7M-$ 9M$ 4M
IPO1996$ 5M-$ 10M$ 12M

Explore beyond GERN

You're looking at Geron Corporation. Members apply the same fundamental framework across all 3,859 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies